Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
5-Amino-1MQ
5-amino-1-methylquinolinium, NNMT inhibitor
A small molecule inhibitor of NNMT (nicotinamide N-methyltransferase), an enzyme that regulates fat cell metabolism and NAD+ availability. While technically a small molecule rather than a peptide, it is commonly grouped with peptide therapies in the metabolic health space due to its mechanism and delivery method.
A modified fragment of human growth hormone (amino acids 177-191) originally developed as an anti-obesity agent. Targets fat metabolism without the growth-promoting effects of full HGH.
Inhibits NNMT, which normally converts NAD+ precursors into methylnicotinamide — a metabolic dead end. By blocking NNMT, 5-Amino-1MQ increases NAD+ availability in fat cells, activating SIRT1 and promoting fat oxidation. Reduces fat cell size and inhibits new fat cell formation (adipogenesis).
Stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat formation) by mimicking the fat-reducing action of natural growth hormone without affecting blood sugar or tissue growth.
- Fat loss and body composition
- Metabolic health improvement
- Obesity treatment (investigational)
- NAD+ pathway optimization
- Fat loss
- Metabolic health
- Body composition improvement
- Cartilage repair (emerging research)
- Very limited human clinical data
- Long-term safety unknown
- Optimal dosing not established
- Potential off-target effects of NNMT inhibition not fully characterized
- Often sourced from gray-market vendors with variable quality
- Limited efficacy data in humans
- Injection site reactions
- Headaches
- Phase 2 trials showed modest results
Not FDA-approved and not on any compounding list. Available as a research chemical. Growing interest in the metabolic health community but human clinical trial data is extremely limited. Not a peptide in the strict sense — a small molecule — but commonly discussed alongside peptide therapies.
Reclassified to Category 1 in February 2026 as part of the HHS announcement restoring compounding access. Not affected by the April 15, 2026 Category 2 removal action. Previously reached Phase 2 clinical trials for obesity but was not pursued further by the original developer. Available through licensed 503A compounding pharmacies with a physician prescription.
- AOD9604 - a novel anti-obesity drug
2001 · PubMed
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.